Brooklyn, United States
Accutar Biotech, founded in 2015, is disrupting the drug discovery industry by employing artificial intelligence to revamp traditional methodologies. Operating from Shanghai, China and New York, NY, the company leverages its AI-driven platforms to significantly cut down on the time and expenses associated with drug discovery.
Specializing in side chain flexible mode ligand docking, virtual screening, and ADME property prediction, Accutar’s solutions, like Chemi-Net and Orbital, outperform the current industry standards in their respective domains. The former is a molecular graph convolutional network improving drug property prediction accuracy, while the latter enhances docking precision in predicting protein-ligand complexes.
The company’s hybrid approach, combining computational design with wet lab validation, is gaining traction within biopharma and biotechnology sectors, evidenced by their $28.45M venture round investment on January 5, 2021. Accutar Biotech is strategically poised to forge strong academic and industry partnerships to solve cross-disciplinary challenges.
